Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.
about
Pregnancy-Associated Changes in Pharmacokinetics: A Systematic ReviewAntiretroviral unbound concentration during pregnancy: piece of interest in the puzzle?Placental transfer of darunavir in an ex vivo human cotyledon perfusion model.Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals.Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2013.Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.Adverse drug reactions associated with antiretroviral therapy during pregnancy.British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review).Antiretroviral Pharmacokinetics in Pregnant Women.Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding.Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women.Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women.Darunavir for Use in Pregnant Women with HIV.Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study.
P2860
Q28109657-183C0979-2975-4102-B3EA-6FDC3970CA07Q33365566-3ECF7EDE-B0CA-4E98-9129-B98944172129Q34057304-DBCA5198-842A-4C33-AE6A-2DBA91374A26Q34429204-4D725414-EDCE-44DA-BD7A-41FE04765CC3Q36084313-4F77A7ED-9539-4CA4-B0ED-E6D9E535C08EQ36599597-0BBF1072-75F6-4BCA-91FF-C6B93BFFA243Q38206255-0800EF80-94E6-45E2-9447-2C90AA844B40Q38222092-34F6E148-294C-4ABD-9034-42498999094CQ38267557-86335906-1496-4F0E-A833-416B929B7783Q38325427-15E78796-12C3-42E7-9E45-26EEE98573EFQ38571596-9C69F075-E009-46D5-BA20-8A1798738622Q38828635-3008B202-5C3D-497B-A312-8020E36851CAQ39759988-976986AF-E683-4557-BC7A-D340576221BCQ41696931-BDD60D09-A34C-4D3E-9BF9-8DDEE20CDD8EQ41922010-C6D32C1F-C0D9-425D-8204-A1B69DE8EB00Q47553402-C873DDB1-6396-4D75-8B3F-C614F2039987
P2860
Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Total and unbound darunavir ph ...... 0 mg administered twice daily.
@ast
Total and unbound darunavir ph ...... 0 mg administered twice daily.
@en
Total and unbound darunavir ph ...... 0 mg administered twice daily.
@nl
type
label
Total and unbound darunavir ph ...... 0 mg administered twice daily.
@ast
Total and unbound darunavir ph ...... 0 mg administered twice daily.
@en
Total and unbound darunavir ph ...... 0 mg administered twice daily.
@nl
prefLabel
Total and unbound darunavir ph ...... 0 mg administered twice daily.
@ast
Total and unbound darunavir ph ...... 0 mg administered twice daily.
@en
Total and unbound darunavir ph ...... 0 mg administered twice daily.
@nl
P2093
P2860
P356
P1433
P1476
Total and unbound darunavir ph ...... 0 mg administered twice daily.
@en
P2093
C D Zorrilla
O O Osiyemi
P Verboven
P2860
P356
10.1111/HIV.12047
P577
2013-06-03T00:00:00Z